Apolipoprotein E

NextCure Provides Business Update and Reports Full Year 2023 Financial Results

Retrieved on: 
Thursday, March 21, 2024
Research, Toxicity, Bone disease, Agreement, Osteogenesis imperfecta, DAR, AML, Risk, Patient, MMAE, Mouse, OI, Public expenditure, Plaque, Apolipoprotein E, PRS, IND, ARIA, GMP, Osteoporosis, CRC, Workforce, Use, ADC, Osteoarthritis, FDA, GLP, Pharmaceutical industry

We plan to present the data of the CRC patients at a scientific conference within the second quarter of 2024.

Key Points: 
  • We plan to present the data of the CRC patients at a scientific conference within the second quarter of 2024.
  • Selected our first antibody drug conjugate (ADC) candidate of a potential of three from our collaboration with LegoChem Biosciences, Inc. (LegoChem).
  • Under the terms of the Agreement, both parties equally share the costs of developing the molecules and profits on commercialized products.
  • Implemented a restructuring plan to reduce operating costs and better align our workforce with the needs of our business.

Beckman Coulter and Fujirebio Expand Partnership to Develop Patient-friendly, Blood-based Neurodegenerative Disease Diagnostics

Retrieved on: 
Tuesday, March 12, 2024
Research, Clinical Trials, Health Technology, Biotechnology, Biometrics, Other Health, Health, Other Science, Science, Neurodegenerative disease, Fujirebio, DirectX, Partnership, Patient, Biomarker, RUO, IVD, Beckman Coulter, Apolipoprotein E, Therapy, Physician, AFL, Amyloid, Medical imaging

Beckman Coulter Diagnostics, a clinical diagnostics leader, and Fujirebio, a leader in neurological markers and In Vitro Diagnostic (IVD) manufacturing, today announced an expansion of their partnership focused on development, manufacturing and clinical adoption of neurodegenerative disease assays.

Key Points: 
  • Beckman Coulter Diagnostics, a clinical diagnostics leader, and Fujirebio, a leader in neurological markers and In Vitro Diagnostic (IVD) manufacturing, today announced an expansion of their partnership focused on development, manufacturing and clinical adoption of neurodegenerative disease assays.
  • In 2023, Beckman Coulter and Fujirebio entered into a collaboration agreement focused on new biomarkers aligned with recently approved monoclonal antibody-based Alzheimer’s disease therapeutics.
  • These new assays are being developed for use on the recently introduced Beckman Coulter DxI 9000 Immunoassay Analyzer.
  • Kevin O’Reilly, President, Beckman Coulter Diagnostics, commented, “We are very excited by our expanded partnership with Fujirebio designed to overcome challenges of developing highly sensitive assays, measuring ultra-low concentrations of neurodegenerative disease biomarkers circulating in the blood stream.”
    “Our expanded partnership with Beckman Coulter will enable increased laboratory, clinician and patient access to more neurodegenerative biomarkers around the world,” stated Monte Wiltse, President & CEO, Fujirebio Diagnostics, Inc. “We look forward to continued collaboration with Beckman Coulter bringing these critical assays to physicians and patients worldwide.”

Beckman Coulter and Fujirebio Expand Partnership to Develop Patient-friendly, Blood-based Neurodegenerative Disease Diagnostics

Retrieved on: 
Tuesday, March 12, 2024
Neurodegenerative disease, Health, Fujirebio, DirectX, Partnership, Patient, Biomarker, Research, RUO, IVD, Beckman Coulter, Apolipoprotein E, Analyser, Therapy, Physician, AFL, Amyloid

BREA, Calif. and TOKYO, March 12, 2024 /PRNewswire/ -- Beckman Coulter Diagnostics, a clinical diagnostics leader, and Fujirebio, a leader in neurological markers and In Vitro Diagnostic (IVD) manufacturing, today announced an expansion of their partnership focused on development, manufacturing and clinical adoption of neurodegenerative disease assays.

Key Points: 
  • BREA, Calif. and TOKYO, March 12, 2024 /PRNewswire/ -- Beckman Coulter Diagnostics, a clinical diagnostics leader, and Fujirebio, a leader in neurological markers and In Vitro Diagnostic (IVD) manufacturing, today announced an expansion of their partnership focused on development, manufacturing and clinical adoption of neurodegenerative disease assays.
  • In 2023, Beckman Coulter and Fujirebio entered into a collaboration agreement focused on new biomarkers aligned with recently approved monoclonal antibody-based Alzheimer's disease therapeutics.
  • Kevin O'Reilly, President, Beckman Coulter Diagnostics, commented, "We are very excited by our expanded partnership with Fujirebio designed to overcome challenges of developing highly sensitive assays, measuring ultra-low concentrations of neurodegenerative disease biomarkers circulating in the blood stream."
  • "Our expanded partnership with Beckman Coulter will enable increased laboratory, clinician and patient access to more neurodegenerative biomarkers around the world," stated Monte Wiltse, President & CEO, Fujirebio Diagnostics, Inc. "We look forward to continued collaboration with Beckman Coulter bringing these critical assays to physicians and patients worldwide."

NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter 2023 Financial Highlights

Retrieved on: 
Monday, November 13, 2023
Apolipoprotein, Risk, AHA, Apolipoprotein B, Cardiovascular disease, History, Patient, American Heart Association, Dyslipidemia, Children of General Hospital, Apolipoprotein E, CETP, ASCVD, Mutation, Moyamoya disease, NAMS, Pharmaceutical industry, Management, MIAMI

NAARDEN, The Netherlands and MIAMI, Nov. 13, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a clinical-stage biopharmaceutical company developing oral, non-statin medicines for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today provided a corporate update and announced financial highlights for the quarter ended September 30, 2023.

Key Points: 
  • “We experienced strong momentum in the third quarter, continuing the foundational work required to scale NewAmsterdam into a robust clinical and commercial organization,” said Michael Davidson, M.D., Chief Executive Officer of NewAmsterdam.
  • “We recently expanded our leadership team with appointments of BJ Jones as Chief Commercial Officer and Ian Somaiya as Chief Financial Officer.
  • In October 2023, NewAmsterdam appointed Ian Somaiya as Chief Financial Officer.
  • Live webcasts of both fireside chats will be available through the investor relations section of the NewAmsterdam Pharma website at ir.newamsterdampharma.com .

NextCure Provides Business Update and Reports Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 2, 2023
Apolipoprotein E, Amyloid, Research, Acute myeloid leukemia, Plaque, Public expenditure, Conference, American Society for Bone and Mineral Research, Society, Osteoporosis, Mouse, ADC, Osteogenesis imperfecta, Annual general meeting, Cancer, Patient, AML, Mineral wool, Pharmaceutical industry, Cryptocurrency

Financial Results for Quarter Ended September 30, 2023

Key Points: 
  • Financial Results for Quarter Ended September 30, 2023
    Cash, cash equivalents, and marketable securities as of September 30, 2023, were $118.2 million as compared to $159.9 million as of December 31, 2022.
  • Research and development expenses were $11.0 million for the quarter ended September 30, 2023, as compared to $13.5 million for the quarter ended September 30, 2022.
  • General and administrative expenses were $4.6 million for the quarter ended September 30, 2023, as compared to $5.7 million for the quarter ended September 30, 2022.
  • Net loss was $14.3 million for the quarter ended September 30, 2023, as compared with a net loss of $18.9 million for the quarter ended September 30, 2022.

Diadem SpA Announces Exclusive U.S. Licensing Agreement with Quest Diagnostics for Its AlzoSure® Predict Alzheimer's Disease Prognostic Technology

Retrieved on: 
Wednesday, October 25, 2023
Knowledge, FDA, Fruit, AD, Ageing, NYSE, Biomarker, CSF, Physician, Apolipoprotein E, Neurology, Data, Conference, AB, Health, Dementia, Protein, PET, Cerebrospinal fluid, DGX, Risk, Marketing, Quest Diagnostics, Test, Diagnosis, Patient, IP, Pharmaceutical industry, Medical imaging, Quest, Alzheimer's disease, Diadem

MILAN and SECAUCUS, N.J., Oct. 25, 2023 /PRNewswire/ -- Diadem SpA, (Diadem), a company developing one of the first blood-based tests for the early and accurate prediction of clinical progression to Alzheimer's disease (AD), today announced that it has formed a strategic collaboration with Quest Diagnostics (NYSE: DGX), the nation's leading provider of diagnostic information services, designed to improve access to high quality blood tests for evaluating the risk of Alzheimer's disease.

Key Points: 
  • Under terms of the agreement, Diadem has licensed exclusive U.S. rights to the intellectual property of its AlzoSure® Predict blood-based prognostic technology to Quest for the purpose of developing, validating and marketing a laboratory-developed test service for providers and patients in the U.S. Financial details of the agreement were not disclosed.
  • "Reliable, convenient and affordable blood tests are essential to the identification of AD risk in early stages, when interventions hold the greatest potential to slow disease progression," said Kathleen Valentine, Vice President and General Manager, Neurology, Quest Diagnostics.
  • Quest Diagnostics has a long-standing history of advancing diagnostic innovation in the field of dementia, including Alzheimer's disease.
  • The company continues to explore the potential of other biomarkers for assessing AD risk that may complement its existing portfolio.

NextCure Presents Preclinical Data on NC181, a Novel Therapeutic Candidate Targeting ApoE4, for the Treatment of Alzheimer’s Disease

Retrieved on: 
Tuesday, September 26, 2023
Apolipoprotein E, CAA, Cerebral amyloid angiopathy, Drug discovery, DSM-IV codes, APOE4, Cancer, Inflammation, Washington University in St. Louis, Dementia, Vasodilation, BBB, Ischemia, Amyloid, Risk, Mouse, AD, APOE, Conference, Disease, Pharmaceutical industry, Vaccine, Medical imaging, Neurology

Deletion of APOE has been demonstrated to limit disease in multiple AD models.

Key Points: 
  • Deletion of APOE has been demonstrated to limit disease in multiple AD models.
  • In preclinical AD animal models, NC181 has demonstrated differentiation from amyloid targeted therapies.
  • Key findings from the study include:
    NC181 binds to amyloid associated ApoE4, resulting in amyloid clearance and prevention of amyloid deposition in mice.
  • Additional studies to characterize NC181 as a potential therapeutic for AD and CAA are ongoing.

NewAmsterdam Pharma Announces Initial Data from Phase 2a Clinical Trial Evaluating Obicetrapib in Patients with Early Alzheimer’s Disease Who Carry an ApoE4 Mutation

Retrieved on: 
Thursday, September 21, 2023
Cognition, Oxysterol, University, Cardiovascular disease, Pathology, Pharmacokinetics, NAMS, Brain, Apolipoprotein, Biomarker, Cerebrospinal fluid, Disability, Reno 1868 FC, Plasma, Patient, CETP, Risk, Lipid metabolism, CSF, AD, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, Food, FESC, Neuroinflammation, Disease, Pharmaceutical industry, Medical imaging, Apolipoprotein E

NAARDEN, The Netherlands and MIAMI, Sept. 21, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a clinical-stage biopharmaceutical company developing oral, non-statin medicines for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced initial data from its Phase 2a clinical trial evaluating obicetrapib in patients with early Alzheimer’s disease (“AD”) and at least one copy of the apolipoprotein E4 mutation (“ApoE4”).

Key Points: 
  • This Phase 2a trial was designed to explore the effects of obicetrapib on lipid metabolism in the brains of early AD patients who are ApoE4 carriers.
  • As such, NewAmsterdam believes reductions of 24- and 27-hydroxycholesterol in the CSF may indicate improved cholesterol metabolism in the brain and may lead to improved cognitive function.
  • NewAmsterdam observed reductions in the levels of 24- and 27-hydroxycholestrol of 11% and 12%, respectively, in the CSF.
  • In addition, an increase of 8% in the Aβ42/40 ratio in patient’s plasma was observed and pTau181 levels were observed to be stable.

Alzheimer's disease is partly genetic − studying the genes that delay decline in some may lead to treatments for all

Retrieved on: 
Saturday, September 16, 2023
Cognition, Uncertainty, Rapunzel's Tangled Adventure (season 2), Apolipoprotein E, Aducanumab, Prevalence, Neurochemistry, Clinical trial, Mutation, Brain, Inflammation, Dementia, Report, Amyloid, Sibling, Patient, Donanemab, Risk, Immune system, Mouse, Observation, FDA, Gene, Family, Food, Safety, Disease, Vaccine, Medical imaging, Agriculture, Pharmaceutical industry

Others are risk genes that affect the body in a way that increases the chance someone will develop the disease.

Key Points: 
  • Others are risk genes that affect the body in a way that increases the chance someone will develop the disease.
  • In Alzheimer’s disease, genetic mutations in any of three specific genes can cause the disease, and other risk genes either increase or decrease the risk of developing Alzheimer’s.
  • Some genetic mutations or variants interact with other genetic alterations that lead to Alzheimer’s disease.

The amyloid hypothesis

    • In the early 1990s, scientists proposed the amyloid hypothesis to explain how Alzheimer’s disease develops.
    • These findings added strength to the amyloid hypothesis explanation of the disease.
    • However, uncertainty and opposition to the amyloid hypothesis have developed over the past several decades.
    • But until a clinical trial based on the amyloid hypothesis could show definitive results, uncertainty would remain.

Genetic discoveries with treatment implications

    • However, a relatively small number of families have one of the three known genetic mutations that cause the disease to be passed down.
    • In familial Alzheimer’s, 50% of each generation will inherit the mutated gene and develop the disease much earlier, usually from their 30s to early 50s.
    • These mutated genes were found in a very large family in Colombia whose members tended to develop Alzheimer’s symptoms by their 40s.
    • A genetic analysis showed that she had an additional mutation in a variant of the gene that codes for a protein called apolipoprotein E, or ApoE.

Starts and stops

    • Although there is still discussion of how much slowing of decline is clinically significant, these successes provide support for the amyloid hypothesis.
    • They also suggest that other strategies will be needed for optimal treatment.
    • The U.S. Food and Drug Administration’s 2021 approval of the first antibody treatment for Alzheimer’s, aducanumab, sold under the brand name Aduhelm, was controversial.

The Korean Society of Ginseng confirms the effects of consuming red ginseng in the prevention and improvement of dementia

Retrieved on: 
Tuesday, September 12, 2023
Rat, Observational study, Mitochondrion, Deficit spending, Research, Hallym University, Natural Product Research, Dementia, EMS, Korea Ginseng Corporation, Apolipoprotein E, Risk, Psychiatry, Ageing, Culture of Korea, Dietary supplement, Alzheimer's disease

SEOUL, South Korea, Sept. 12, 2023 /PRNewswire/ -- Through continuous research, the secrets of ginseng, a representative medicinal herb of Korea, are being revealed, showcasing its efficacy. Recently, studies demonstrating the effects of consistent consumption of red ginseng on improving dementia and cognitive function have been announced one after another, attracting attention.

Key Points: 
  • Recently, studies demonstrating the effects of consistent consumption of red ginseng on improving dementia and cognitive function have been announced one after another, attracting attention.
  • The Korean Society of Ginseng's spring academic conference in 2023 witnessed Konyang University's Institute for Alzheimer's & Dementia Research and Korea Ginseng Corporation's Natural Products Research Institute revealing the mechanism by which ginsenoside compounds in ginseng reduce cognitive impairment in Alzheimer's disease.
  • Among individuals without the Apolipoprotein E4 gene mutation, which increases the risk of late-onset Alzheimer's disease, consuming Korean ginseng was found to be effective in improving EMS.
  • These research results demonstrate the potential utility of ginseng as a candidate for preventing and improving conditions like dementia and mild cognitive impairment.